GV and Novo-backed cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.
US-based cardiovascular disease therapy developer Verve Therapeutics is going public today in a $267m initial public offering representing exits for internet and technology group Alphabet and pharmaceutical firm Novo. The offering consists of just over 14 million shares issued on the Nasdaq Global Select Market, increased from 11.8 million and priced at $19.00 each, above…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.